These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 37262000)

  • 21. Barriers to the Treatment of Hepatitis C among Predominantly African American Patients Seeking Care in an Urban Teaching Hospital in Washington, D.C.
    Liu L; Daftary MN; Alzahrani MS; Ohanele C; Maneno MK
    J Natl Med Assoc; 2021 Apr; 113(2):147-157. PubMed ID: 32868101
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vital signs: evaluation of hepatitis C virus infection testing and reporting - eight U.S. sites, 2005-2011.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2013 May; 62(18):357-61. PubMed ID: 23657111
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Population Level Cascade of Care for Hepatitis C in British Columbia, Canada: The BC Hepatitis Testers Cohort (BC-HTC).
    Janjua NZ; Kuo M; Yu A; Alvarez M; Wong S; Cook D; Wong J; Grebely J; Butt ZA; Samji H; Ramji A; Tyndall M; Krajden M
    EBioMedicine; 2016 Oct; 12():189-195. PubMed ID: 27596150
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of the Impact of Mandating Health Care Providers to Offer Hepatitis C Virus Screening to All Persons Born During 1945-1965 - New York, 2014.
    Flanigan CA; Leung SJ; Rowe KA; Levey WK; King A; Sommer JN; Morne JE; Zucker HA
    MMWR Morb Mortal Wkly Rep; 2017 Sep; 66(38):1023-1026. PubMed ID: 28957037
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hepatitis C virus care cascade in persons experiencing homelessness in the United States in the era of direct-acting antiviral agents: A scoping review.
    Del Rosario A; Eldredge JD; Doorley S; Mishra SI; Kesler D; Page K
    J Viral Hepat; 2021 Nov; 28(11):1506-1514. PubMed ID: 34314081
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterizing the cascade of care for hepatitis C virus infection among Status First Nations peoples in Ontario: a retrospective cohort study.
    Mendlowitz AB; Bremner KE; Krahn M; Walker JD; Wong WWL; Sander B; Jones L; Isaranuwatchai W; Feld JJ
    CMAJ; 2023 Apr; 195(14):E499-E512. PubMed ID: 37040993
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pragmatic Experience with Risk-based versus Universal Hepatitis C Screening in Pregnancy: Detection of Infection and Postpartum Linkage to Care.
    Bushman ET; Subramani L; Sanjanwala A; Dionne-Odom J; Franco R; Owen J; Subramaniam A
    Am J Perinatol; 2021 Sep; 38(11):1109-1116. PubMed ID: 33934324
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictors of hepatitis C treatment outcomes in a harm reduction-focused primary care program in New York City.
    Ziff J; Vu T; Dvir D; Riazi F; Toribio W; Oster S; Sigel K; Weiss J
    Harm Reduct J; 2021 Mar; 18(1):38. PubMed ID: 33789691
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessment of Treatment Strategies to Achieve Hepatitis C Elimination in Canada Using a Validated Model.
    Binka M; Janjua NZ; Grebely J; Estes C; Schanzer D; Kwon JA; Shoukry NH; Kwong JC; Razavi H; Feld JJ; Krajden M
    JAMA Netw Open; 2020 May; 3(5):e204192. PubMed ID: 32374397
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatitis C treatment uptake among patients who have received methadone substitution treatment in the Republic of Georgia.
    Stvilia K; Vephkvadze N; Gamkrelidze A; Khonelidze I; Getia V; Tsereteli M; Gvinjilia L; Kuchuloria T
    Public Health; 2021 Jun; 195():42-50. PubMed ID: 34051674
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modelling the elimination of hepatitis C as a public health threat in Iceland: A goal attainable by 2020.
    Scott N; Ólafsson S; Gottfreðsson M; Tyrfingsson T; Rúnarsdóttir V; Hansdottir I; Hernandez UB; Sigmundsdóttir G; Hellard M
    J Hepatol; 2018 May; 68(5):932-939. PubMed ID: 29274408
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The impact of direct-acting anti-virals on the hepatitis C care cascade: identifying progress and gaps towards hepatitis C elimination in the United States.
    Chhatwal J; Chen Q; Bethea ED; Hur C; Spaulding AC; Kanwal F
    Aliment Pharmacol Ther; 2019 Jul; 50(1):66-74. PubMed ID: 31115920
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Implementing a new HCV model of care for people who use drugs.
    Herranz Mochales A; Picchio CA; Nicolàs A; Macià MD; Fernández-Baca MV; Serrano J; Bonet L; Trelles M; Sansó A; Rubí AR; Zamora A; García-Gasalla M; Buti M; Vilella À; Lazarus JV
    JHEP Rep; 2024 Oct; 6(10):101145. PubMed ID: 39308984
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An intervention to increase hepatitis C virus diagnosis and treatment uptake among people in custody in Iran.
    Hariri S; Alavi M; Roshandel G; Mohammadi Z; Fazel A; Amiriani T; Bazazan A; Motamed-Gorji N; Sohrabpour A; Merat S; Poustchi H; Malekzadeh R
    Int J Drug Policy; 2021 Sep; 95():103269. PubMed ID: 33991887
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection.
    Foster GR; Pianko S; Brown A; Forton D; Nahass RG; George J; Barnes E; Brainard DM; Massetto B; Lin M; Han B; McHutchison JG; Subramanian GM; Cooper C; Agarwal K;
    Gastroenterology; 2015 Nov; 149(6):1462-70. PubMed ID: 26248087
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial.
    Liu CH; Liu CJ; Lin CL; Liang CC; Hsu SJ; Yang SS; Hsu CS; Tseng TC; Wang CC; Lai MY; Chen JH; Chen PJ; Chen DS; Kao JH
    Clin Infect Dis; 2008 Nov; 47(10):1260-9. PubMed ID: 18834319
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Birth Cohort Testing for Hepatitis C Virus - Indian Health Service 2012-2015.
    Reilley B; Leston J; Hariri S; Neel L; Rudd M; Galope M; Ward J; Vellozzi C
    MMWR Morb Mortal Wkly Rep; 2016 May; 65(18):467-9. PubMed ID: 27171026
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Implementation of Liver Cancer Education Among Health Care Providers and Community Coalitions in the Cherokee Nation.
    Momin B; Mera J; Essex W; Gahn D; Burkhart M; Nielsen D; Mezzo J; Millman AJ
    Prev Chronic Dis; 2019 Aug; 16():E112. PubMed ID: 31441770
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment outcomes of patients with chronic hepatitis C receiving sofosbuvir-based combination therapy within national hepatitis C elimination program in the country of Georgia.
    Tsertsvadze T; Gamkrelidze A; Nasrullah M; Sharvadze L; Morgan J; Shadaker S; Gvinjilia L; Butsashvili M; Metreveli D; Kerashvili V; Ezugbaia M; Chkhartishvili N; Abutidze A; Kvaratskhelia V; Averhoff F
    BMC Infect Dis; 2020 Jan; 20(1):30. PubMed ID: 31924172
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Outreach onsite treatment with a simplified pangenotypic direct-acting anti-viral regimen for hepatitis C virus micro-elimination in a prison.
    Chen CT; Lu MY; Hsieh MH; Tsai PC; Hsieh TY; Yeh ML; Huang CI; Tsai YS; Ko YM; Lin CC; Chen KY; Wei YJ; Hsu PY; Hsu CT; Jang TY; Liu TW; Liang PC; Hsieh MY; Lin ZY; Huang CF; Huang JF; Dai CY; Chuang WL; Shih YL; Yu ML
    World J Gastroenterol; 2022 Jan; 28(2):263-274. PubMed ID: 35110949
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.